BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says

MT Newswires Live01-14

BioMarin Pharmaceuticals (BMRN) is aiming for continued growth in 2026 after pre-announcing 2025 revenue in line with expectations and highlighting its goal of sustained double-digit long-term revenue growth into the 2030s, Wedbush Securities said in a Tuesday note.

BioMarin remains confident in keeping Voxzogo's leadership in achondroplasia, expanding into hypochondroplasia and other skeletal indications, and accelerating growth from the Amicus acquisition, according to the report.

The brokerage also noted the company highlighting positive pipeline progress, including early dystrophin expression data for BMN-351 in Duchenne muscular dystrophy and updated pharmacokinetic results for BMN-333.

Despite intensifying competition in achondroplasia, Wedbush believes Voxzogo's broad label, high patient compliance, and strong ex-US footprint provide advantages.

The firm maintained its outperform rating on the stock with a price target of $94.

Shares of the company were down nearly 5% in recent trading.

Price: 55.00, Change: -2.72, Percent Change: -4.70

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603630389?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 04:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603630389","market":"fut","top_or_hot":-1,"title":"BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> BioMarin Pharmaceuticals (BMRN) is aiming for continued growth in 2026 after pre-announcing 2025 revenue in line with expectations and highlighting its goal of sustained double-digit long-term revenue growth into the 2030s, Wedbush Securities said in a Tuesday note.</p><p>BioMarin remains confident in keeping Voxzogo's leadership in achondroplasia, expanding into hypochondroplasia and other skeletal indications, and accelerating growth from the Amicus acquisition, according to the report.</p><p>The brokerage also noted the company highlighting positive pipeline progress, including early dystrophin expression data for BMN-351 in Duchenne muscular dystrophy and updated pharmacokinetic results for BMN-333.</p><p>Despite intensifying competition in achondroplasia, Wedbush believes Voxzogo's broad label, high patient compliance, and strong ex-US footprint provide advantages.</p><p>The firm maintained its outperform rating on the stock with a price target of $94.</p><p>Shares of the company were down nearly 5% in recent trading.</p><p>Price: 55.00, Change: -2.72, Percent Change: -4.70</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-14 04:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BioMarin Pharmaceuticals (BMRN) is aiming for continued growth in 2026 after pre-announcing 2025 revenue in line with expectations and highlighting its goal of sustained double-digit long-term revenue growth into the 2030s, Wedbush Securities said in a Tuesday note.</p><p>BioMarin remains confident in keeping Voxzogo's leadership in achondroplasia, expanding into hypochondroplasia and other skeletal indications, and accelerating growth from the Amicus acquisition, according to the report.</p><p>The brokerage also noted the company highlighting positive pipeline progress, including early dystrophin expression data for BMN-351 in Duchenne muscular dystrophy and updated pharmacokinetic results for BMN-333.</p><p>Despite intensifying competition in achondroplasia, Wedbush believes Voxzogo's broad label, high patient compliance, and strong ex-US footprint provide advantages.</p><p>The firm maintained its outperform rating on the stock with a price target of $94.</p><p>Shares of the company were down nearly 5% in recent trading.</p><p>Price: 55.00, Change: -2.72, Percent Change: -4.70</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZLL34.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603630389","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603630389","pubTimestamp":1768335643,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioMarin Pharmaceuticals  is aiming for continued growth in 2026 after pre-announcing 2025 revenue in line with expectations and highlighting its goal of sustained double-digit long-term revenue growth into the 2030s, Wedbush Securities said in a Tuesday note.BioMarin remains confident in keeping Voxzogo's leadership in achondroplasia, expanding into hypochondroplasia and other skeletal indications, and accelerating growth from the Amicus acquisition, according to the report.The brokerage also noted the company highlighting positive pipeline progress, including early dystrophin expression data for BMN-351 in Duchenne muscular dystrophy and updated pharmacokinetic results for BMN-333.Despite intensifying competition in achondroplasia, Wedbush believes Voxzogo's broad label, high patient compliance, and strong ex-US footprint provide advantages.The firm maintained its outperform rating on the stock with a price target of $94.Shares of the company were down nearly 5% in recent trading.Pri","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4566":"资本集团","BMRN":"拜玛林制药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4139":"生物科技"},"translate_title":"Wedbush表示，BioMarin Pharmaceuticals的目标是在2026年实现持续增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":1},"content_text":"BioMarin Pharmaceuticals (BMRN) is aiming for continued growth in 2026 after pre-announcing 2025 revenue in line with expectations and highlighting its goal of sustained double-digit long-term revenue growth into the 2030s, Wedbush Securities said in a Tuesday note.BioMarin remains confident in keeping Voxzogo's leadership in achondroplasia, expanding into hypochondroplasia and other skeletal indications, and accelerating growth from the Amicus acquisition, according to the report.The brokerage also noted the company highlighting positive pipeline progress, including early dystrophin expression data for BMN-351 in Duchenne muscular dystrophy and updated pharmacokinetic results for BMN-333.Despite intensifying competition in achondroplasia, Wedbush believes Voxzogo's broad label, high patient compliance, and strong ex-US footprint provide advantages.The firm maintained its outperform rating on the stock with a price target of $94.Shares of the company were down nearly 5% in recent trading.Price: 55.00, Change: -2.72, Percent Change: -4.70","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603630389","isCrawlerRequest":true}